Overview
SonoThera, Inc. is a pioneering biotechnology company dedicated to advancing ultrasound-guided, nonviral gene therapies. The company's innovative platform is designed to circumvent the limitations of existing gene therapy techniques through a non-invasive, targeted delivery method for genetic medicines. Established in South San Francisco, California, SonoThera aims to develop genetic treatments targeting the root causes of human diseases.
Contact Information
- Address: 201 Haskins Way, Fifth Floor, South San Francisco, CA
- Website: [sonothera.com](https://sonothera.com)
- Contact: +1 415 376 7840
- Email: [INFO@SONOTHERA.COM](mailto:INFO@SONOTHERA.COM)
Leadership and Key Personnel
- Kenneth Greenberg, Ph.D.: Co-founder and Chief Executive Officer. With a strong history in biotech entrepreneurship and prior senior roles in R&D, Dr. Greenberg has guided SonoThera's development since June 2022.
- Carolyne Zimmermann: Chief Business Officer. She has extensive experience in business development from 4D Molecular Therapeutics, joining SonoThera in June 2023.
- Steve Feinstein: Chief Scientific Officer, leading scientific strategy and innovation.
- Zoya Gluzman-Poltorak: Chief Development Officer focusing on development execution and pipeline enhancement.
- John McKeon: VP of Finance & Controller, overseeing the company's financial operations.
- Barry Campbell: Senior Director with a key role in research and business advancement.
- Ivan Krivega: Director of Gene Therapy, providing expertise in genetic therapy projects.
- Maria Konovalenko: Manager of Operations and Strategy, ensuring operational efficiency.
- Rosa Meza-Acevedo: Lab Manager, responsible for laboratory operations.
Recent Developments
Funding and Financial Overview
- Series A Funding: SonoThera successfully closed a $60.75 million Series A funding round to propel its gene therapy platform development. The total investment raised, including this round, stands at $61 million, with backing from ARCH Venture Partners and Alexandria Venture Investments.
- Financial Metrics: The company has an estimated annual revenue of $2.4 million, with a workforce of 31 employees, reflecting a 41% increase in staff this year. The revenue per employee is approximately $77,500.
Strategic Collaborations
- Janssen Pharmaceuticals, Inc.: Ongoing research collaboration aimed at enhancing SonoThera's gene therapy capabilities.
- Lantheus Partnership: Utilization of Lantheus's microbubble technology to bolster SonoThera's nonviral gene therapy platform.
Industry Engagement
- Recognized as one of the BioSpace NextGen Class of 2024 Top Life Sciences Startups, affirming the company's innovative approach in genetic medicine.
Technology and Services
SonoThera's platform uniquely combines ultrasound with microbubble-enhanced delivery, enabling precise and efficient delivery of genetic materials. This method effectively addresses the challenges posed by traditional viral delivery systems, aiming for safer and more efficient treatment of a range of genetic disorders.
Competitor Profiling
Major Competitors:
1. DiaCarta: Operates in Precision Molecular Diagnostics with an estimated revenue of $4.4 million and a staff of 57. Based in Pleasanton, CA.
2. Mission Bio: Specializes in multi-omics single-cell technology, boasting an estimated revenue of $21.2 million and 137 employees, headquartered in South San Francisco, CA.
3. StrideBio: Focuses on gene therapy for rare diseases with $8 million in revenue, based in Durham, NC.
4. Quadrants Scientific: Involved in chemical testing and environmental monitoring with $0.9 million in revenue.
Additional competitors in the biotechnology and genetic therapy space include LogicBio, Phase Genomics, Calcilytix Ther, Ravata Solution, Range Biotechnology, Mission Barns, Geron Corporation, Mindstrong, and CalciMedica.
Strategic Positioning
SonoThera, through its collaborative partnerships and focus on nonviral gene therapies, positions itself competitively in the biotech sector. This strategic direction, aligned with competitors like DiaCarta and Mission Bio, underscores its commitment to innovations that capitalize on the growing demand for precision medicine and genetic therapies. The leadership team's strategic vision, coupled with innovative technology, continues to position SonoThera for success and industry influence.
